Browsing by title
Now showing items 827-846 of 4595
-
Chromosome-level assembly of Arabidopsis thaliana Ler reveals the extent of translocation and inversion polymorphisms.
(NATL ACAD SCIENCES, 2016-07-12)Resequencing or reference-based assemblies reveal large parts of the small-scale sequence variation. However, they typically fail to separate such local variation into colinear and rearranged variation, because they usually ... -
Circulating anti-Müllerian hormone and breast cancer risk: A study in ten prospective cohorts.
(WILEY, 2018-06-01)A strong positive association has been observed between circulating anti-Müllerian hormone (AMH), a biomarker of ovarian reserve, and breast cancer risk in three prospective studies. Confirming this association is important ... -
Circulating biomarkers of neuroendocrine prostate cancer: an unmet challenge.
(WILEY-BLACKWELL, 2017-01-01) -
Circulating cell-free DNA methylation analysis of metastatic prostate cancer
(Institute of Cancer Research (University Of London), 2020-03-31)Introduction; Materials and methods; Deciphering global plasma DNA methylation variance in metastatic prostate cancer; Implementation of a methylation signature for tracking and detection of prostate cancer in plasma; ... -
Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition.
(AMER ASSOC CANCER RESEARCH, 2017-09-01)Biomarkers for more precise patient care are needed in metastatic prostate cancer. We have reported a phase II trial (TOPARP-A) of the PARP inhibitor olaparib in metastatic prostate cancer, demonstrating antitumor activity ... -
Circulating cell-free DNA: Translating prostate cancer genomics into clinical care.
(ELSEVIER, 2020-04-01)Only in the past decade tremendous advances have been made in understanding prostate cancer genomics and consequently in applying new treatment strategies. As options regarding treatments are increasing so are the challenges ... -
Circulating Growth and Sex Hormone Levels and Breast Tissue Composition in Young Nulliparous Women.
(AMER ASSOC CANCER RESEARCH, 2018-12-01)BACKGROUND: Endogenous hormones are associated with breast cancer risk, but little is known about their role on breast tissue composition, a strong risk predictor. This study aims to investigate the relationship between ... -
Circulating Metabolic Biomarkers of Screen-Detected Prostate Cancer in the ProtecT Study.
(AMER ASSOC CANCER RESEARCH, 2019-01-01)BACKGROUND: Whether associations between circulating metabolites and prostate cancer are causal is unknown. We report on the largest study of metabolites and prostate cancer (2,291 cases and 2,661 controls) and appraise ... -
Circulating microRNA-652-3p as a biomarker of regorafenib resistance in metastatic colorectal cancer patients
(Institute of Cancer Research (University Of London), 2020-09-30)MicroRNAs (miRNAs) are small non-coding RNAs involved in cell homeostasis. MiRNAs dysregulation has been linked with activation of oncogenic pathways, cancer progression and clinical outcome in metastatic colorectal cancer ... -
Circulating tumor cells, tumor-derived extracellular vesicles and plasma cytokeratins in castration-resistant prostate cancer patients.
(Impact Journals, LLC, 2018-04-10)PURPOSE: The presence of Circulating Tumor Cells (CTCs) in Castration-Resistant Prostate Cancer (CRPC) patients is associated with poor prognosis. In this study, we evaluated the association of clinical outcome in 129 CRPC ... -
Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review.
(COLL AMER PATHOLOGISTS, 2018-03-05)PURPOSE.—: Clinical use of analytical tests to assess genomic variants in circulating tumor DNA (ctDNA) is increasing. This joint review from the American Society of Clinical Oncology and the College of American Pathologists ... -
Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review.
(LIPPINCOTT WILLIAMS & WILKINS, 2018-06-01)Purpose Clinical use of analytical tests to assess genomic variants in circulating tumor DNA (ctDNA) is increasing. This joint review from ASCO and the College of American Pathologists summarizes current information about ... -
Circulating Tumor DNA Markers for Early Progression on Fulvestrant With or Without Palbociclib in ER+ Advanced Breast Cancer.
(OXFORD UNIV PRESS INC, 2021-03-01)BACKGROUND: There are no established molecular biomarkers for patients with breast cancer receiving combination endocrine and CDK4/6 inhibitor (CDK4/6i). We aimed to determine whether genomic markers in circulating tumor ... -
Circulating tumour cell increase as a biomarker of disease progression in metastatic castration-resistant prostate cancer patients with low baseline CTC counts.
(ELSEVIER, 2018-07-01)BACKGROUND: The development of treatment response and surrogate biomarkers for advanced prostate cancer care is an unmet clinical need. Patients with baseline circulating tumour cell (BLCTCs) counts <5/7.5 mL represent a ... -
Circulating tumour DNA analysis in advanced breast cancer
(Institute of Cancer Research (University Of London), 2022-10-17)Circulating tumour DNA (ctDNA) analysis shows great potential both as an approach to understand the evolution of advanced breast cancer (ABC) and as a clinical tool to assist in ABC management. ctDNA analysis has not yet ... -
Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial.
(ELSEVIER SCIENCE INC, 2020-10-01)BACKGROUND: Circulating tumour DNA (ctDNA) testing might provide a current assessment of the genomic profile of advanced cancer, without the need to repeat tumour biopsy. We aimed to assess the accuracy of ctDNA testing ... -
Circulating tumour DNA in advanced thyroid cancer
(Institute of Cancer Research (University Of London), 2021-02-28)Conventional biomarkers currently used in thyroid cancer are not disease specific and fluctuate in advanced disease, making interpretation difficult. Circulating tumour DNA (ctDNA) has been shown to be a useful in other ... -
Circulating Tumour DNA in Muscle-Invasive Bladder Cancer.
(MDPI, 2018-08-29)Circulating tumour DNA (ctDNA) is an attractive tool in cancer research, offering many advantages over tissue samples obtained using traditional biopsy methods. There has been increasing interest in its application to ... -
Circulating tumour DNA is a potential biomarker for disease progression and response to targeted therapy in advanced thyroid cancer.
(ELSEVIER SCI LTD, 2018-11-01)BACKGROUND: Conventional biomarkers in thyroid cancer are not disease specific and fluctuate in advanced disease, making interpretation difficult. Circulating tumour DNA (ctDNA) has been shown to be a useful biomarker in ... -
Circulating Tumour DNA Sequencing Identifies a Genetic Resistance-Gap in Colorectal Cancers with Acquired Resistance to EGFR-Antibodies and Chemotherapy.
(MDPI, 2020-12-11)Epidermal growth factor receptor antibodies (EGFR-Abs) confer a survival benefit in patients with RAS wild-type metastatic colorectal cancer (mCRC), but resistance invariably occurs. Previous data showed that only a minority ...